Processa Pharmaceuticals Statistics
Total Valuation
PCSA has a market cap or net worth of $4.66 million. The enterprise value is -$4.12 million.
| Market Cap | 4.66M |
| Enterprise Value | -4.12M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PCSA has 2.86 million shares outstanding. The number of shares has increased by 116.63% in one year.
| Shares Outstanding | 2.86M |
| Shares Change (YoY) | +116.63% |
| Shares Change (QoQ) | +75.12% |
| Owned by Insiders (%) | 12.11% |
| Owned by Institutions (%) | 3.72% |
| Float | 2.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.70, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.70 |
| Quick Ratio | 8.85 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -130.10% and return on invested capital (ROIC) is -110.55%.
| Return on Equity (ROE) | -130.10% |
| Return on Assets (ROA) | -115.90% |
| Return on Capital (ROIC) | -110.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$755,833 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.52% in the last 52 weeks. The beta is 0.60, so PCSA's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -81.52% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 4.50 |
| Relative Strength Index (RSI) | 41.38 |
| Average Volume (20 Days) | 42,447 |
Short Selling Information
The latest short interest is 68,410, so 2.39% of the outstanding shares have been sold short.
| Short Interest | 68,410 |
| Short Previous Month | 142,163 |
| Short % of Shares Out | 2.39% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 0.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.98M |
| Pretax Income | -9.83M |
| Net Income | -9.83M |
| EBITDA | -9.74M |
| EBIT | -9.83M |
| Earnings Per Share (EPS) | -$6.39 |
Balance Sheet
The company has $8.92 million in cash and $140,380 in debt, giving a net cash position of $8.78 million or $3.07 per share.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | 140,380 |
| Net Cash | 8.78M |
| Net Cash Per Share | $3.07 |
| Equity (Book Value) | 8.88M |
| Book Value Per Share | 3.11 |
| Working Capital | 8.79M |
Cash Flow
| Operating Cash Flow | -8.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | -8.00M |
| FCF Per Share | -$3.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PCSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -116.63% |
| Shareholder Yield | -116.63% |
| Earnings Yield | -210.92% |
| FCF Yield | -171.69% |
Analyst Forecast
The average price target for PCSA is $6.00, which is 268.10% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 268.10% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 22, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 22, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |